Ge Long Hui·2025-08-22 09:47Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., has received drug registration certificates from the Philippines Food and Drug Administration for its Oxytocin Injection and Acetate Octreotide Injection, allowing these products to be marketed [1] Group 1: Product Details - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing complications after pancreatic surgery, and managing esophageal variceal bleeding [1] Group 2: Development Background - Oxytocin Injection was developed by PAR STERILE PRODUCTS and was first launched in the United States in 1980 [1] - Acetate Octreotide Injection was developed by NOVARTIS and was first launched in the United States in 1988 [1]